Pinealon

Pinealon has been given to people, but the human record is small, loosely described and hard to pin on this one peptide. The only human study read in full summary is a 2015 Russian paper on 32 adults aged 41 to 83 with several chronic illnesses and organic brain syndrome in remission. It gave pinealon and a second short peptide, vesugen, and measured biological age indicators, not symptoms or function. A 2020 review by the peptide's developers also describes 72 patients with the after-effects of traumatic brain injury who took pinealon by mouth alongside standard treatment, but only as a one-paragraph summary.

Almost everything else is cells and rats, and nearly all of it carries the name of one St. Petersburg institute, the Institute of Bioregulation and Gerontology, and its long-time head author Vladimir Khavinson. The findings there are specific: less oxidative damage in stressed neurons in a dish, and better maze learning in rat pups exposed to high homocysteine before birth.

Pinealon is not approved by the FDA, does not appear anywhere on FDA's 503A nominations list, and is prohibited at all times in tested sport under WADA's S0 class.

Pinealon is a three amino acid peptide: glutamic acid, aspartic acid, arginine, written Glu-Asp-Arg or EDR. Its developers describe it as a tripeptide isolated from Cortexin, a polypeptide brain preparation used as a neuroprotective drug in Russia, and a 2024 paper describes EDR as coming from polypeptide complexes of calf cerebral cortex.

It belongs to a family the same school calls peptide bioregulators, short synthetic sequences each tied to an organ or tissue. Vesugen (KED) and epitalon (AEDG) are relatives; the 2024 cell study tested all three side by side. That shared origin is the main fact to hold onto when reading the citations: the studies are real, and most of them come from the people who made the peptide.

What the Developers Propose

The most detailed account is a 2020 review by Khavinson and three colleagues, all listing the St. Petersburg Institute of Bioregulation and Gerontology. They propose that EDR enters the cytoplasm and the nucleus, binds histone proteins or nucleic acids, and changes the expression of genes involved in neuronal survival and antioxidant defence. The proteins they list include the MAPK/ERK pathway, caspase-3 and p53, the antioxidant enzymes SOD2 and GPX1, PPARA and PPARG, serotonin and calmodulin. They also cite in vitro work in which EDR interacted with DNA, and mouse hippocampal neuron cultures modelling Alzheimer's disease in which it prevented the loss of mushroom-shaped dendritic spines. The review itself frames the nuclear route as presumed rather than demonstrated.

What the Cell Work Measured

The 2011 Rejuvenation Research paper, with Khavinson as first author, exposed rat cerebellar granule cells, neutrophils and PC12 pheochromocytoma cells to oxidative stress. Pinealon restricted reactive oxygen species build-up in a dose-dependent way, reduced necrotic cell death, delayed activation of the ERK 1/2 kinases and altered the cell cycle. Because the antioxidant effect levelled off at low concentrations while the cell-cycle effect kept rising at higher ones, the authors concluded the peptide acts on the genome as well as scavenging free radicals. That is an inference from a pattern, not a direct observation of the peptide binding DNA in those cells.

The overreach here is less about invented evidence and more about stretching real but narrow findings.

Calling it clinically proven for the brain. The human reports are a 32-person study whose outcome was biological age indicators, and a 72-patient result known only from its developers' review. Neither is a randomised placebo-controlled trial of pinealon on its own.

Crediting pinealon with a two-peptide result. The 2015 study used pinealon and vesugen, and its own abstract says vesugen showed the more visible effect.

Treating citation count as confirmation. The cell, rat and review papers share authors and an institution. Several reports from one group agreeing with each other is not the same as an outside lab reproducing the result.

Moving rat pups and cultured neurons into adults. The maze result came from offspring of mothers with induced high homocysteine, and the gap closed by the fifth trial. The dendrite and DNA damage results came from neurons in a dish made from three donors' skin cells.

Treating a proposed gene-regulation mechanism as established. The developers present nuclear entry as presumed. A three-residue peptide steering gene expression would be a notable finding that still waits on independent confirmation.

Human safety information is thin. The 2015 study reports no adverse event list in its English abstract, but it does report pro-oxidant activity and a fall in CD34+ blood stem cells that the authors themselves called significant inhibition of blood cell formation, in people who also received vesugen. The review's 72-patient summary does not mention side effects either way. No source here describes long-term use.

No pinealon product is approved by the FDA, so material sold online has no reference standard for identity, purity or dose. Pinealon does not appear on FDA's Category 1 or Category 2 lists or anywhere else in the 503A nominations; FDA has said it does not intend to categorise substances nominated on or after 7 January 2025, so that absence says nothing about safety or legality.

WADA does not name pinealon on the 2026 Prohibited List. Section S0 prohibits at all times any pharmacological substance with no current approval from a governmental health authority for human therapeutic use, which covers it.

People have taken pinealon, in Russian clinical settings, and the reports are positive on their own terms. Those terms are loose: biological age indices, a second peptide in the mix, no described placebo arm, and one result known only secondhand.

What the evidence supports: in rat and human-derived cells under stress, EDR reduced oxidant build-up and cell death, and in fibroblast-derived neurons from older women it lengthened dendrites. In rat pups exposed to high homocysteine before birth, maternal pinealon was linked to faster early maze learning. What it does not support: any claim that pinealon improves memory, slows brain ageing or protects against dementia in adults. No controlled trial has put those questions to pinealon, and the research base still runs through one institute.

Not tested alone in a controlled human trial. The 2015 study used pinealon with vesugen and measured biological age indicators, and the 72-patient report gives no comparison group.

Not independently replicated. The 2011, 2012, 2020 and 2024 laboratory and review papers all include authors from the St. Petersburg Institute of Bioregulation and Gerontology, three of them with Khavinson among them.

Not a proven cognitive enhancer. The maze benefit was seen in rat pups after a prenatal homocysteine insult and had disappeared by the fifth trial.

Not an approved medicine or permitted in sport. It has no FDA approval, sits nowhere on the 503A nominations list, and falls under WADA's S0 class.

I place pinealon at early human data because people have been given it and outcomes were recorded. I do not let that label do more work than it can. One study mixed it with another peptide and scored biological age; the other reached me only through its developers' summary.

What I respect is that the lab work is specific and some of it is honest about null results, like the 2024 paper reporting no change in mitochondria, lysosomes or p16. What holds me back is that nearly every paper traces to one institute. If a group with no tie to St. Petersburg runs a controlled trial of pinealon alone, I will rewrite this with whatever confidence it earns.